CLPT
ClearPoint Neuro, Inc.
CLPT's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over CLPT overall, supported by stronger fundamentals and lower modeled downside.
CLPT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
CLPT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLPT PE Valuation
CLPT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CLPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CLPT's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CLPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.20 | -$0.36 |
| Q2 2026 | -$1.17 | -$0.36 |
| Q1 2026 | -$1.00 | -$0.24 |
| Q4 2025 | -$0.90 | -$0.20 |
| Q3 2025 | -$0.84 | -$0.16 |
| Q2 2025 | -$0.81 | -$0.11 |
| Q1 2025 | -$0.76 | +$0.07 |
| Q4 2024 | -$0.70 | +$0.20 |
CLPT lost $1.20 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CLPT on earnings quality, reporting a profit while its opponent remains loss making.
CLPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.1M | +36% |
| Q2 2026 | $10.9M | +18% |
| Q1 2026 | $12.1M | +43% |
| Q4 2025 | $10.4M | +34% |
| Q3 2025 | $8.9M | +9.1% |
| Q2 2025 | $9.2M | +17% |
| Q1 2025 | $8.5M | +11% |
| Q4 2024 | $7.8M | +14% |
CLPT's revenue has grown year over year every quarter since late 2020: $12M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -52% | +7.1 points |
| Q2 2026 | -94% | -33 points |
| Q1 2026 | -70% | +2.7 points |
| Q4 2025 | -68% | +4.4 points |
| Q3 2025 | -60% | +4.1 points |
| Q2 2025 | -62% | -1.3 points |
| Q1 2025 | -73% | -17 points |
| Q4 2024 | -72% | -3 points |
CLPT's operating margin was −52% last quarter, up 7.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CLPT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CLPT on profitability, with a higher operating margin.
CLPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | -$16.9M |
| Q2 2026 | -$7.2M | -$4.6M |
| Q1 2026 | -$8.6M | -$2.3M |
| Q4 2025 | -$12.1M | -$10.6M |
| Q3 2025 | -$3.3M | -$2.1M |
| Q2 2025 | -$2.6M | +$25K |
| Q1 2025 | -$6.4M | -$2.5M |
| Q4 2024 | -$1.5M | -$316K |
CLPT has burned cash in almost every quarter: −$48M over the past year, against −$14M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CLPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +817K shares |
| 1 year | +9% | +2.6M shares |
| 3 years | +26% | +6.4M shares |
| 5 years | +38% | +8.5M shares |
| Available history | +136% | +17.8M shares |
CLPT has 31M diluted shares, up 9% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CLPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CLPT Net Leverage
CLPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CLPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 9.1 | Oversold |
CLPT's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CLPT PE vs Healthcare Sector
CLPT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CLPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 17% below |
| 20 week MA | $13.2 | 36% below |
| 50 week MA | $13.0 | 34% below |
| 100 week MA | $13.8 | 39% below |
| 200 week MA | $10.8 | 22% below |
CLPT is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CLPT on trend strength, trading above more of its moving averages.
CLPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $13.8 | +175% |
| 2021 | $13.8 | $11.8 | -15% |
| 2022 | $11.8 | $7.96 | -32% |
| 2023 | $7.96 | $6.79 | -15% |
| 2024 | $6.79 | $15.8 | +132% |
| 2025 | $15.8 | $14.0 | -11% |
| 2026 YTD | $14.0 | $8.49 | -39% |
CLPT has finished lower in four of the last six years. It's down 39% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CLPT on returns for 2026, with the stronger performance.